<DOC>
	<DOC>NCT01476657</DOC>
	<brief_summary>The purpose of this study is to determine the safety, maximum tolerated dose and pharmacokinetics of IPI-145 in patients with advanced hematologic malignancies.</brief_summary>
	<brief_title>A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>≥ 18 years of age; Progressed during, refractory to, intolerant of, or ineligible for established therapy, or has a disease with no established therapy with the exception of expansion cohort of treatment naïve CLL patients; An Eastern Cooperative Oncology Group (ECOG) score of 0 to 2. Any previous treatment with a PI3K inhibitor (Escalation Phase only) or within 4 weeks of the start of IPI145 administration (Expansion Phase); Patients with overt leptomeningeal leukemia or CNS lymphoma; Inadequate hepatic function defined by aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt; 2.5 x upper limit of normal (ULN); direct bilirubin &gt;1.5 x ULN; Inadequate renal function defined by serum creatinine &gt; 1.5 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Phase 1</keyword>
</DOC>